For example, tyrosine kinase inhibitors (TKIs) are examples that are mostly administered to Her-2+ patients and TKIs have shown an improved progression-free survival in Her-2+ breast cancer brain metastases [105]. Here, ERBB2 is linked to breast carcinoma.